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MaThe duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with
apparently conﬂicting results. Although longer exposure associates with more bleeding complications, late stent
thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of
ST compared with the ﬁrst-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better
protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be
shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the
most recent studies. (J Am Coll Cardiol 2015;66:832–47) © 2015 by the American College of Cardiology Foundation.C urrently, dual antiplatelet therapy (DAPT)refers to the addition of a P2Y12 platelet re-ceptor inhibitor (either a thienopyridine
[clopidogrel or prasugrel] or the cyclopentyl-
triazolopyrimidine, ticagrelor) to aspirin, aiming to
reduce stent thrombosis (ST) after coronary stent im-
plantation and prevent coronary atherothrombotic
events at sites outside of the stented segment.
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
BMS = bare-metal stent(s)
CAD = coronary artery disease
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
L-DAPT = long duration of
dual antiplatelet therapy
(12 months)
MI = myocardial infarction
S-DAPT = short duration of
dual antiplatelet therapy
(£6 months)
ST = stent thrombosis
VL-DAPT = very long duration
of dual antiplatelet therapy
(>12 months)
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833as SAPT; continuation of P2Y12 inhibition as mono-
therapy is yet to be studied.
ISSUES WITH DAPT FOR
CORONARY STENTING
HISTORICAL CONSIDERATIONS ON DAPT. Clopidogrel
was ﬁrst shown to be more effective than aspirin in
reducing ischemic stroke, myocardial infarction (MI),
or vascular death in patients with a prior athero-
thrombotic event (2). Then, in 2001, the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent
Events) study investigators reported that the combi-
nation of clopidogrel and aspirin resulted in a 2%
absolute reduction in the risk of cardiovascular death,
MI, and stroke in patients with an acute coronary
syndrome (ACS) at the expense of an absolute 1%
increase in the risk of major bleeding versus aspirin
alone (3,4). The percutaneous coronary intervention
(PCI)-CURE substudy, in which 82% of patients
received a bare-metal stent (BMS), found that adding
clopidogrel to aspirin reduced the composite of car-
diovascular death, MI, and revascularization within
the ﬁrst 30 days after patients underwent PCI (5).
After the CREDO (Clopidogrel for the Reduction of
Events During Observation) study demonstrated that
12 months of DAPT after elective PCI reduced the
incidence of death, MI, and stroke by 27% when
compared with DAPT administered for 30 days fol-
lowed by aspirin alone (6), DAPT became the standard
of care for the ﬁrst year after an ACS (7) on the
grounds that DAPT attenuated recurrent ischemic
events. At that time, the mandatory duration of DAPT
for ST prevention was only 1 month.
FIRST CONCERNS ABOUT THE EFFICACY OF SHORT-
DURATION DAPT. Drug-eluting stents (DES) were
approved after the demonstration that the frequency
of in-stent restenosis was reduced compared with
BMS. Some 3 years later, it was recognized that
although the restenosis beneﬁt extended beyond
12 months, patients with DES were at continuously
higher risk of MI and death after the conversion from
DAPT to SAPT, presumably due to late ST (8). Late ST
was attributed to delayed stent endothelialization,
and was encountered 2.75more often with DES than
with BMS. The U.S. Food and Drug Administration’s
(FDA) 2006 advisory on DES recommended DAPT for
12 months after implantation on the basis of broad
expert consensus (9).
Although reports vary, the frequency of ST after
DES implantation is probably around 0.5% to 2%
per annum and is more prevalent after an ACS
(8,10,11). Although a number of risk factors for ST
have been identiﬁed (12,13), it is neither possible topredict its occurrence accurately nor
possible to prevent it entirely with DAPT
(14). Despite the low frequency of late ST, it
is associated with high rates of acute MI
and death. This concern led the FDA to
initiate a trial on duration of DAPT after
stenting.
FIRST CONCERNS ABOUT THE SAFETY OF
PROLONGED DAPT. Safety concerns with
prolonged DAPTwere raised in the CHARISMA
(Clopidogrel for High Atherothrombotic Risk
and Ischemic Stabilization, Management,
and Avoidance) study (1). Although DAPT
did not provide signiﬁcant protection against
ischemic events in patients with stable
vascular disease or at risk of atherothrombotic
events, it was associated with a signiﬁcant
60% excess of moderate bleeding and a non-
signiﬁcant excess of severe or fatal bleeding
complications (15). A meta-analysis also sug-
gested harm with prolonged DAPT (16).
Combined antiplatelet therapy was also tested with
vorapaxar, an antagonist of protease-activated recep-
tor type 1 receptors. The primary efﬁcacy endpoint—a
composite of cardiovascular death, MI, or stroke—was
signiﬁcantly reduced with vorapaxar in addition to
aspirin, dipyridamole, thienopyridine, or a combina-
tion of these antiplatelet agents in patients with stable
atherosclerosis, but it also increased the risk of
moderate or severe bleeding, including intracranial
hemorrhage (17). In both trials, the issue of safety was
less pronounced in patients with symptomatic ath-
erothrombosis or MI.
The recent demonstration that the new second-
generation DES reduces ST compared with ﬁrst-
generation paclitaxel-eluting stents (PES) suggests
better protection against ST in the future, in partic-
ular with the newer cobalt-chromium everolimus-
eluting stents (EES) (18,19). A series of randomized
studies were then launched to test whether DAPT
for <12 months might improve the net clinical beneﬁt
after DES implantation.
CURRENT INTERNATIONAL SOCIETY
GUIDELINES ON DAPT DURATION
U.S. GUIDELINES. On revascular i zat ion . In relation
to the duration of antiplatelet therapy, the 2011 U.S.
guidelines on PCI (Table 1) (20) assigned a Class I
recommendation to the following strategies:
 Aspirin should be continued indeﬁnitely after PCI.
 P2Y12 inhibition should be continued for at least
12 months after PCI for ACS.
TABLE 1 Guideline Recommendations on Duration of Dual Antiplatelet Therapy Post-Stenting
Patient Subpopulation U.S. Guidelines
European Society of
Cardiology Guidelines
U.K. National Institute for
Health and Care Excellence Australian Guidelines
Stent (BMS or DES) in
patients with ACS
At least 12 months (COR I, LOE: B). Longer durations may
be considered in patients with DES (COR IIb, LOE: C)
Up to 12 months (COR I,
LOE: A)
Up to 12 months* 12 months (COR I, LOE: B)†
BMS in non-ACS At least 1 month (minimum 2 weeks if increased bleeding
risk, ideally up to 12 months) (COR I, LOE: B)
At least 1 month (COR I,
LOE: A)
According to device-speciﬁc
instructions*
Endorses U.S. guideline*
DES in non-ACS At least 12 months (COR I, LOE: B) 6 months (COR I, LOE: B) At least 12 months* Endorses U.S. guideline*
Secondary prevention May be considered (COR IIb, LOE: B) Selected patients at high
risk of ischemic events*
Not recommended beyond
12 months*
Consider in patients with
recurrent ischemic
events*
*No COR or LOE provided. †COR and LOE adapted from Australian National Health and Medical Research Council guidelines (87).
ACS ¼ acute coronary syndrome(s); BMS ¼ bare-metal stent(s); COR ¼ class of recommendation; DES ¼ drug-eluting stent(s); LOE ¼ Level of Evidence.
Montalescot et al. J A C C V O L . 6 6 , N O . 7 , 2 0 1 5
Duration of DAPT After Coronary Stenting A U G U S T 1 8 , 2 0 1 5 : 8 3 2 – 4 7
834 If a DES is placed for a non-ACS indication, clopi-
dogrel should be administered for at least 12
months if patients are not at high risk of bleeding.
 In patients receiving a BMS for a non-ACS indica-
tion, clopidogrel should be administered for at least
1 month (a minimum of 2 weeks in patients at
increased bleeding risk) and ideally up to 12months.
These guidelines suggest that it is reasonable to
stop P2Y12 inhibition earlier than 12 months if the risk
of bleeding outweighs the anticipated beneﬁt of
continuing the second antiplatelet agent. However,
extending DAPT beyond 12 months may be consid-
ered in patients at high risk of ST and/or low risk of
bleeding after DES implantation. This latter recom-
mendation is endorsed in the more recent 2014 AHA/
ACC Guideline for the Management of Patients With
Non–ST-Elevation Acute Coronary Syndromes (21–23).
On secondary prevent ion . The 2011 U.S. secondary
prevention guidelines address the duration of anti-
platelet therapy in patients with stable CAD (24).
Using evidence from the CHARISMA trial, it lends
support to combining aspirin and clopidogrel in this
population.
EUROPEAN GUIDELINES. On revascular izat ion . The
2014 European guidelines on myocardial revasculari-
zation, incorporating evidence from studies published
between 2011 and 2013 that highlight bleeding hazards
associated with DAPT (Table 1) (25), differ from the
U.S. guidelines in recommending DAPT for amaximum
of 12 months after ACS, for only 1 month after BMS
implantation for non-ACS indications, and for only
6 months after DES for non-ACS indications.
On secondary prevent ion . The 2013 recommenda-
tions concerning DAPT in the management of stable
CAD (26) cite post-hoc analyses from CHARISMA and
TRA-2P TIMI-50 (Thrombin Receptor Antagonist in
Secondary Prevention of Atherothrombotic Ischemic
Events) (17), concluding that although DAPT may be
beneﬁcial in selected patients at high risk of ischemicevents, it cannot be recommended systematically in
patients with stable CAD.
OTHER GUIDELINES. In the United Kingdom, guid-
ance regarding stenting has not been updated since
2008, and the recommendations broadly align with
those of the United States (27–29). DAPT is not rec-
ommended for patients more than 12 months post-MI.
Australian guidelines broadly reﬂect those of the
United States (30,31), although they uniquely recom-
mend long-term DAPT for secondary prevention in
patients with recurrent ischemic events (32).
STUDIES EVALUATING A
3- TO 6-MONTH DURATION OF DAPT
STUDIES. On the basis of the lower risk of ST with
second-generation DES and the reduction of bleeding
events with a short duration (S)-DAPT strategy, these
studies tested the hypothesis that combining
frequent (if not exclusive) use of latest-generation
DES with DAPT for <12 months (S-DAPT) would
result in an improved net clinical beneﬁt for patients.
Net clinical beneﬁt, combining both ischemic and
bleeding complications, was chosen as the primary
endpoint in 5 of the 7 studies.
The ﬁrst study assessing S-DAPT was the EXCELLENT
(Comparison of the Efﬁcacy of Everolimus-Eluting
Versus Sirolimus-Eluting Stent for Coronary Lesions)
trial (Table 2) (33). A total of 50% of patients pre-
sented with ACS. An EES was implanted in 75% of
patients and a sirolimus-eluting stent (SES) in the
remainder.
Subsequently, the PRODIGY (PROlonging Dual
Antiplatelet Treatment In Patients With Coronary
Artery Disease After Graded Stent-induced Intimal
Hyperplasia) and RESET (A New Strategy Regarding
Discontinuation of Dual Antiplatelet; Real Safety and
Efﬁcacy of a 3-month Dual Antiplatelet Therapy
Following Zotarolimus-eluting Stents Implantation)
studies were published (34,35). The PRODIGY trial
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835was a 4-by-2 randomized, open-label, multicenter
trial that evaluated the efﬁcacy and safety of 6 versus
24 months of DAPT in an all-comer population
receiving a balanced mixture of stents. Patients
undergoing PCI were 1:1:1:1 randomized to receive 1 of
4 stent types, including BMS, EES, PES and the
Endeavor zotarolimus-eluting stent (ZES) (Medtronic,
Inc., Santa Rosa, California). More than 70% of
patients presented with ACS. The RESET trial was the
ﬁrst study evaluating a mandatory DAPT duration of
3 months with a second-generation DES (35). Patients,
55% of whom had ACS, were randomized in a 1:1
fashion to either an Endeavor ZES with DAPT for
3 months or an EES, Resolute ZES (Medtronic), or SES
with DAPT for 12 months.
OPTIMIZE (Optimized Duration of Clopidogrel
Therapy Following Treatment With the Endeavor
Zotarolimus-Eluting Stent in the Real World Clinical
Practice) was another study to evaluate 3 months of
mandatory DAPT (36). It was a multicenter, open-
label, randomized trial evaluating 3 versus 12 months
of DAPT in patients, of whom 32% had ACS, although
none had MI.
In 2014, the SECURITY (Second-Generation Drug-
Eluting Stent Implantation Followed by 6- Versus
12-Month Dual Antiplatelet Therapy), ITALIC (Is There
A LIfe for DES After Discontinuation of Clopidogrel),
and ISAR-SAFE (Randomized, Double-Blind, Placebo-
controlled Trial of 6 vs. 12 Months Clopidogrel Therapy
After Implantation of a Drug-Eluting Stent) trials
(37–39) reported on evaluating S-DAPT for 6 months
versus 12 months. SECURITY was a randomized, open-
label multicenter study evaluating the safety and
efﬁcacy of 6 months versus 12 months of DAPT in
patients undergoing PCI with a second-generation
DES. This study included the largest proportion of
bioresorbable polymer DES. The ITALIC study evalu-
ated 6 months versus 24 months of DAPT after Xience
EES (Abbott Vascular, Santa Clara, California) implan-
tation. Randomization occurred at the time of the in-
dex procedure, and results have so far been reported
only up to 1-year follow-up. Interestingly, ITALIC
excluded patients resistant to aspirin. The prevalence
of ACS at baseline was low (24%). Finally, ISAR-SAFE
was a multicenter, double-blind, placebo-controlled,
randomized trial testing the efﬁcacy and safety of
6 months versus 12 months of DAPT. Only patients on
DAPT who were event-free in the ﬁrst 6 months after
DES implantation were randomized to either continue
with DAPT or be treated with aspirin and placebo. A
total of 72% had received second-generation DES. The
prevalence of ACS at presentation before the index
procedure was 40% (8% ST-segment elevation acute
coronary syndrome [STEMI] and 32% non-STEMI).
TABLE 3
Trial (Re
ISAR-SAFE
ITALIC (38
SECURITY
OPTIMIZE
PRODIGY
RESET (35
EXCELLEN
Total
Values are n
ARI ¼ abs
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836Noninferiority of the primary endpoint for S-DAPT
versus long duration (L)-DAPT was demonstrated in
each of these studies irrespective of stent type, clin-
ical indication, or DAPT duration. Moreover, no dif-
ferences were observed in the components of the
primary endpoint, ST or bleeding, in most of the
studies. The PRODIGY trial was the only exception, in
which 24 months of DAPT was associated with higher
rates of major bleeding than 6-month DAPT. Most
probably, the statistical signiﬁcance for higher risk of
bleeding with L-DAPT in this study was related to the
longer exposure in the L-DAPT group compared with
the S-DAPT group, as neither group reﬂected standard
practice (i.e., 1-year DAPT) as deﬁned by contempo-
rary guidelines. Of note, prolonged DAPT provided
ischemic beneﬁt in certain subgroups—for example,
diabetic patients in the EXCELLENT trial and patients
with in-stent restenosis target lesions in the PRODIGY
trial (33,40).
Accepting differences in study design and baseline
clinical risk proﬁle, when pooling the events from
all 7 studies (Table 3), S-DAPT (3 or 6 months)
was associated with an overall rate of ST of 0.5%
compared with 0.4% with L-DAPT (absolute risk
reduction with L-DAPT: 0.1%). The pooled rate of MI
was 1.7% with S-DAPT and 1.5% with L-DAPT (abso-
lute risk reduction: 0.2%). The rate of major bleeding
was 0.4% with S-DAPT and 0.8% with L-DAPT (ab-
solute risk increase with L-DAPT: 0.4%), whereas the
death rate was 1.7% with S-DAPT and 1.9% with
L-DAPT (absolute risk increase: 0.2%). These results
suggest a risk/beneﬁt ratio favoring an S-DAPT
regimen (Figure 1). Recently published meta-analyses
report similar ﬁndings (41,42).
CLINICAL INTERPRETATION. Several issues must be
considered when interpreting results from these
trials evaluating the safety and efﬁcacy of S-DAPT
(3 to 6 months). First, all were underpowered to
detect differences in hard endpoints, including theEndpoints in Studies Evaluating Abbreviated Duration of DAPT (#6 Mo
f. #)
Stent Thrombosis MI
S-DAPT L-DAPT ARR S-DAPT L-DAPT ARR
(39) 5 (0.3) 4 (0.2) 0.1 13 (0.7) 14 (0.7) 0
) 3 (0.3) 0 0.3 6 (0.7) 4 (0.4) 0.
(37) 2 (0.3) 3 (0.4) 0.1 16 (2.3) 15 (2.1) 0.
(36) 13 (0.8) 12 (0.8) 0 49 (3.2) 42 (2.7) 0.
(34) 15 (1.5) 13 (1.3) 0.2 41 (4.2) 39 (4) 0.
) 2 (0.2) 3 (0.3) 0.1 2 (0.2) 4 (0.4) 0.
T (33) 6 (0.9) 1 (0.1) 0.8 13 (1.8) 7 (1) 0.
46 (0.5) 36 (0.4) 0.1 140 (1.7) 125 (1.5) 0.
(%).
olute risk increase; ARR ¼ absolute risk reduction; L-DAPT ¼ long dual antiplatelet therapycomposite primary endpoints. The low statistical po-
wer among studies was related to study design issues,
slow enrollment, premature interruption of several
studies, lower than expected event rates, and
possibly, under-reporting. Second, with 1 exception,
all studies were open-label trials, introducing the
potential for observer bias. Third, treatment cross-
over, selection bias, and regression to the mean
pose problems, as a not insigniﬁcant proportion of
patients who were randomized to the S-DAPT arm
were still on DAPT at the end of the follow-up period
(and vice-versa). Fourth, most of these trials had only
1 year of follow-up, which is insufﬁcient to evaluate
very late clinical outcomes. Fifth, the number of pa-
tients lost to follow-up was not always reported and,
when reported, was as high as 7%. Sixth, all of the
previous issues have a particularly deleterious effect
on studies with a noninferiority design; the 7 studies
considered here had a noninferiority design with
wide noninferiority margins. Seventh, except for the
PRODIGY trial, results from these studies lack
external validity (generalizability), as high-risk pa-
tients were excluded from the majority. Finally, pri-
mary endpoint deﬁnitions were heterogeneous; some
studies included target vessel revascularization, and
others did not include ST in the composite endpoint.
Considering these potential limitations, results
from S-DAPT trials must be evaluated carefully. As
each individual study is inconclusive for events like
MI or major bleeding, meta-analytic methods may
more reliably approximate the true risk/beneﬁt bal-
ance of S-DAPT (Figures 2 and 3). There was no excess
risk of MI with S-DAPT, but there was a signiﬁcant
reduction in major bleeding, conﬁrmed recently in
several pooled analyses of these studies (41,42). All of
these meta-analyses have serious limitations related
to heterogeneity in study designs, populations, deﬁ-
nitions of events, and lengths of follow-up, in addi-
tion to the limitations of the individual studiesnths) After DES
Major Bleeding Death
S-DAPT L-DAPT ARI S-DAPT L-DAPT ARI
4 (0.2) 5 (0.3) 0.1 8 (0.4) 12 (0.6) 0.2
3 5 (0.5) 7 (0.7) 0.2 8 (0.9) 7 (0.8) 0.1
2 4 (0.6) 8 (1.1) 0.5 8 (1.2) 8 (1.2) 0
5 10 (0.6) 14 (0.9) 0.3 43 (2.8) 45 (2.9) 0.1
2 6 (0.6) 16 (1.6) 1 65 (6.6) 65 (6.6) 0
2 5 (0.5) 10 (1) 0.5 5 (0.5) 8 (1) 0.5
8 4 (0.6) 10 (1.4) 0.8 4 (0.6) 7 (1) 0.4
2 38 (0.4) 70 (0.8) 0.4 141 (1.7) 152 (1.9) 0.2
; S-DAPT ¼ short dual antiplatelet therapy; other abbreviations as in Tables 1 and 2.
FIGURE 1 Net Clinical Beneﬁt of Longer DAPT in Studies Evaluating a Period of
DAPT #6 Months
Net Clinical Benefit for L-DAPT Versus S-DAPT in Short-Term Studies
4.5
Harm
Neutrality
Benefit
4
3.5
3
2.5
2
1.5
1
0.5
0
NNT / NNH
ST / MB
4 2 2 1
ST / Death MI / MB MI / Death
For each ST prevented with L-DAPT, 4 major bleeding events or 2 deaths would be caused.
DAPT ¼ dual antiplatelet therapy; L-DAPT ¼ long dual antiplatelet therapy; MB ¼ major
bleeding; MI ¼ myocardial infarction; NNH ¼ number needed to harm; NNT ¼ number
needed to treat; S-DAPT ¼ short dual antiplatelet therapy; ST ¼ stent thrombosis.
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837outlined earlier. However, they provide additional
information that no individual study on its own can
provide.
The beneﬁts of prolonged DAPT may be more
evident in studies of ﬁrst-generation DES, in which
incomplete strut coverage and delayed vascular heal-
ing increase the risk of late ST (43), whereas signiﬁcant
improvement in safety with second-generation DES
has been demonstrated (18,44). Moreover, DAPT
duration and DES generation interact to attenuate late
ST (45). Accordingly, a short mandatory period of
DAPT of 3 or 6 months may be considered safe and
effective in non-ACS patients undergoing PCI with
latest-generation DES, in particular in patients at risk
of bleeding and/or at low risk of recurrent ischemia.
This may ﬁnd much wider application henceforth
because ﬁrst-generation DES are no longer routinely
implanted.
STUDIES EVALUATING A DURATION
LONGER THAN 12 MONTHS
STUDIES. Characteristics and major ﬁndings of
the trials evaluating DAPT durations longer than
12 months (very long [VL]-DAPT) are summarized in
Table 4. These studies evaluated patients who had
completed 1 year of DAPT without ischemic or
bleeding complications, perhaps implying selection
of a lower-risk population.
The DES-LATE (Optimal Duration of Clopidogrel
Therapy With DES to Reduce Late Coronary Arterial
Thrombotic Event) trial was a prospective, multi-
center, open-label, randomized trial to determine the
beneﬁts and risks of continuing DAPT beyond 1 year
after DES insertion (n ¼ 5,045) (46). This trial was a
seamless extension of the previously conducted
REAL-LATE (Correlation of Clopidogrel Therapy
Discontinuation in Real-World Patients Treated
with Drug-Eluting Stent Implantation and Late
Coronary Arterial Thrombotic Events) and ZEST-
LATE (Evaluation of the Long-Term Safety after
Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent,
or Paclitaxel-Eluting Stent Implantation for Coronary
Lesions—Late Coronary Arterial Thrombotic Events)
studies. It concluded that, compared with aspirin
alone, continuing DAPT beyond 1 year after DES
implantation was not beneﬁcial (47). Both ﬁrst- and
second-generation DES were used. At 2 years after
randomization, the rate of the primary endpoint
(death, MI, or stroke) was similar between the aspirin-
alone and DAPT groups (2.4% vs. 2.6%, respectively;
p ¼ 0.75). The rate of Thrombolysis In Myocardial
Infarction (TIMI) major bleeding was also similar
between the aspirin-alone and DAPT groups (1.1% vs.1.4%; p ¼ 0.20). These ﬁndings suggest that the 2
antiplatelet strategies provide similar protection
against ischemic events with similar risk of bleeding
events.
ARCTIC (Assessment by a double Randomization
of a Conventional antiplatelet strategy versus a
monitoring-guided strategy for drug-eluting stent
implantation and of Treatment Interruption versus
Continuation 1 year after stenting)-Interruption was a
prospective, multicenter, open-label randomized
study (48) that was a planned extension of the
ARCTIC-Monitoring trial, which had randomly allo-
cated 2,440 patients to a strategy of platelet function
testing with antiplatelet treatment adjustment or a
conventional antiplatelet strategy without moni-
toring after coronary stenting with DES (49). After
1 year, 1,259 eligible patients were randomized in the
ARCTIC-Interruption trial. After a median follow-up
of another 17 months, 78% of patients in the contin-
uation group were still on thienopyridine, and the
rate of the primary endpoint (death, MI, ST, stroke, or
urgent revascularization) was similar between the
interruption L-DAPT group and the continuation
VL-DAPT group (4% vs. 4%; p ¼ 0.58). Major bleeding
events tended to occur more frequently with
VL-DAPT than with L-DAPT (1% vs. <0.5%; p ¼ 0.073);
major or minor bleeding events were signiﬁcantly
increased with VL-DAPT, suggesting possible harm
with no tangible beneﬁt from a VL-DAPT strategy.
The DAPT trial, a large, international, multicenter,
randomized, placebo-controlled trial, was designed to
determine the beneﬁts and risks of continuing
DAPT beyond 1 year after the placement of a coronary
FIGURE 2 MI in the Meta-Analysis of L-DAPT Versus S-DAPT for Studies With
S-DAPT for #6 Months
Odds
ratio
All
EXCELLENT 1.870 0.742 4.715
1.773
2.728
2.191
1.655
1.986
5.333
1.446
0.1 1
Favors
short
Favors
long
10
p=0.30
0.768
0.091
0.622
0.676
0.436
0.422
0.891
1.167
0.499
1.167
1.058
0.931
1.500
1.135
OPTIMIZE
RESET
SECURITY
PRODIGY
ISAR-SAFE
ITALIC
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Reproduced with permission from Montalescot G. Risk and beneﬁt of dual antiplatelet
therapy. Paper presented at: the American Heart Association, Late Breaking Clinical Trial
session; November 16, 2014. EXCELLENT ¼ Efﬁcacy of Xience/Promus Versus Cypher to
Reduce Late Loss After Stenting; ISAR-SAFE ¼ Randomized, Double-Blind, Placebo-
controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-
Eluting Stent; ITALIC ¼ Is There A LIfe for DES After Discontinuation of Clopidogrel;
OPTIMIZE ¼ Optimized Duration of Clopidogrel Therapy Following Treatment With the
Endeavor Zotarolimus-Eluting Stent in the Real World Clinical Practice; PRODIGY ¼
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After
Graded Stent-induced Intimal Hyperplasia; RESET ¼ A New Strategy Regarding Discon-
tinuation of Dual Antiplatelet; Real Safety and Efﬁcacy of a 3-month Dual Antiplatelet
Therapy Following Zotarolimus-eluting Stents Implantation; SECURITY ¼ Second-
Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Anti-
platelet Therapy; other abbreviations as in Figure 1.
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838DES (50). At 12 months after DES implantation,
9,961 patients who had not had a major ischemic or
bleeding event and had been adherent to DAPT were
assigned to continue thienopyridine and aspirin
treatment (VL-DAPT arm) or to receive placebo plus
aspirin for the next 18 months (L-DAPT arm). The
coprimary efﬁcacy endpoints were ST and the com-
posite of death, MI, or stroke during the period from
12 to 30 months after DES implantation. The primary
safety endpoint was moderate or severe bleeding. As
secondary analyses, examination of the same end-
points in all patients over the course of the 21-month
post-randomization period was undertaken, during
the last 3 months of which the patients were not
receiving randomized treatment (to assess potential
hazards before and after discontinuation of the study
drug for qualitative differences). As a primary result,
continuing thienopyridine, as compared with pla-
cebo, reduced the rates of both coprimary endpoints,
ST (0.4% vs. 1.4%; p < 0.001) and death, MI, or stroke
(4.3% vs. 5.9%; p < 0.001). Continued thienopyridineincreased the rate of moderate or severe bleeding
(2.5% vs. 1.6%; p ¼ 0.001). An increased risk of ST
and MI was observed in both groups during the
3 months after stopping thienopyridine. A borderline
increase in all-cause mortality was observed with
continued thienopyridine (2.0%) versus placebo (1.5%;
p ¼ 0.052).
All 3 trials evidently studied patients who were at
lower risk for late adverse events. The screening
period of the ARCTIC-Interruption trial corresponded
with the ﬁrst phase of the trial. One year after stent-
ing, 47% of the patients were excluded from the
second randomization evaluating VL-DAPT. In the
DAPT study, 22,866 patients were deemed eligible for
the study, but a year later, 56% were excluded at the
time of randomization for the evaluation of VL-DAPT.
Although the 2 study designs differ, these 2 enroll-
ment processes clearly indicate the difﬁculties in
conducting such trials and the super-selection of
patients who ﬁnally participated in the evaluation of
VL-DAPT.
When considering the 3 trials together, there was
a reduction of MI or ST with VL-DAPT, but an
increase of major bleeding and, possibly, of all-cause
death when compared with L-DAPT. Meta-analysis
(Figure 4) indicates a trend toward higher risk of all-
cause mortality associated with the use of VL-DAPT.
This ﬁnding on mortality remains controversial
because of the criteria used to select the studies
incorporated in different meta-analyses, some sug-
gesting harm with prolonged DAPT after stenting,
others not conﬁrming the harm associated with pro-
longed DAPT (41,52). The recent PEGASUS-TIMI 54
(Prevention of Cardiovascular Events in Patients With
Prior Heart Attack Using Ticagrelor Compared to Pla-
cebo on a Background of Aspirin-Thrombolysis In
Myocardial Infarction 54) study is reassuring, with
favorable trends on mortality with prolonged DAPT in
post-MI patients (51).
CLINICAL INTERPRETATION. The DES-LATE trial
included mostly ﬁrst-generation DES, patients pre-
senting with ACS, and a DAPT regimen using clopi-
dogrel exclusively, which may have reduced the effect
of prolonged DAPT in preventing ischemic events
when compared with the more potent P2Y12 inhibitors
now available (i.e., prasugrel or ticagrelor). When
compared with other studies performed in Western
populations, the event rates in the DES-LATE study
were lower and could be explained by the East Asian
paradox (53): the fact that East Asian patients have a
similar or even lower rate of ischemic events after
stenting compared with Caucasians, despite greater
platelet reactivity on DAPT treatment. VL-DAPT did
not provide incremental beneﬁt to the subgroup
FIGURE 3 Major Bleeding in the Meta-Analysis of S-DAPT Versus L-DAPT for Studies
With S-DAPT for #6 Months
Odds
ratio
All
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Reproduced with permission from Montalescot G. Risk and beneﬁt of dual antiplatelet
therapy. Paper presented at: the American Heart Association, Late Breaking Clinical Trial
session; November 16, 2014. Abbreviations as in Figures 1 and 2.
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839of patients with clinical or angiographic high-risk fea-
tures. High on-treatment platelet reactivity did not
help identify optimal candidates for VL-DAPT.
The ARCTIC-Interruption trial was underpowered
and published simultaneously with a meta-analysis
conﬁrming the main ﬁndings of the trial, in particular
the safety concern regarding VL-DAPT. Measurement
of platelet reactivity was another unique aspect of the
ARCTIC-Interruption trial. Although high platelet
reactivity was shown to be a marker for ischemic
events and was strongly associated with mortality,
platelet reactivity did not differ between the continu-
ation and interruption groups, and there was no
interaction between interruption and platelet reac-
tivity on clinical outcomes. Once again, platelet reac-
tivity did not assist in selecting patients for VL-DAPT.
The DAPT study is the largest and only double-
blinded trial. DAPT is the only study adequately
powered for its primary endpoints (ST and major
adverse cardiac and cerebrovascular events [MACCE])
and also for major bleeding. Both ﬁrst- and second-
generation DES types were used, and clopidogrel
and prasugrel were both utilized. Continued thieno-
pyridine attenuated ischemic events, including late
ST; the demonstration of a “rebound” in ischemic
events after interruption more than 2 years after
stenting adds to the concept of ongoing protection
with VL-DAPT. Moreover, the reduction of MI
originated within the stented artery as frequently
as within the nonstented arteries, suggesting that
there is a secondary prevention effect of a VL-DAPT
strategy. The PEGASUS-TIMI 54 study, using tica-
grelor in addition to aspirin in secondary prevention
on average 4 years after an MI, lends additional
support to the hypothesis that VL-DAPT provides
better global protection (51). Whether these ﬁndings
substantiate “indeﬁnite” DAPT treatment after DES in
selected patients remains uncertain. The effects on
ST and MACCE were very consistent across the DAPT
trial subgroups, suggesting that the results may not
be conﬁned to any speciﬁc patient proﬁle. Unex-
pectedly, VL-DAPT was not better in patients with
risk factors for ST and tended to be even less effective
in diabetic patients (p value for interaction ¼ 0.01).
Similarly, the excess of GUSTO (Global Utilization
of Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries) moderate/severe
bleeding complications with VL-DAPT was consistent
across subgroups, not identifying proﬁles of patients
at particular excess bleeding risk with VL-DAPT.
In this regard, the remaining question is how
robust the ﬁnding of excess mortality with VL-DAPT
is in this large trial. It should be recognized that this
is a weak signal derived from a small number ofevents appearing late in follow-up. Fatal bleeding
(Bleeding Academic Research Consortium 5) oc-
curred in 0.15% versus 0.09% (p ¼ 0.38) for the
30-month versus the 12-month period of DAPT. The
excess of deaths from any cause with VL-DAPT was
driven by an increase in noncardiovascular deaths.
The reasons identiﬁed could be related to bleeding,
trauma, or cancer, while accepting that some of the
trauma- or cancer-related deaths were also related
to, revealed, or accentuated by bleeding. There
was an asymmetrical split in fatal bleeding (21
with VL-DAPT vs. 5 with L-DAPT) when all non-
cardiovascular deaths were considered. There were
also more cancer-related deaths among patients on
VL- than L-DAPT (31 vs. 14; p ¼ 0.02, including 3 vs.
0 bleeding-related deaths) although the incidence of
cancer did not differ signiﬁcantly at the time of
randomization. The relationship between major
bleeding and death, which is widely documented in
the published data, appears to be present here again,
although causality cannot be ascertained. The same
trend is present in the meta-analysis of the 3 studies,
which examined VL-DAPT after DES (Figure 4).
However, a large and more global meta-analysis of 14
trials that randomly assigned 69,644 participants to
extended-duration DAPT for various medical condi-
tions showed that it was not associated with a dif-
ference in the risk of all-cause, cardiovascular, or
noncardiovascular death compared with aspirin
alone or short-duration DAPT (52). Although the
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840question remains open, it is fair to state that no
survival beneﬁt may be expected from administering
VL-DAPT after DES.
Registry data also have shown conﬂicting results
on the optimal duration of DAPT (54,55). The large
PARIS (Patterns of Non-Adherence to Anti-Platelet
Regimens In Stented Patients) registry also assessed
associations between the different modes of DAPT
cessation and cardiovascular risk over 2 years after
PCI. The overall incidence of any DAPT cessation was
57.3%, and cardiac events differed according to the
mode of dual antiplatelet cessation and diminished
over time (56).
EVIDENCE AND EXTRAPOLATIONS
TYPE OF STENT. In the DAPT study, VL-DAPT
reduced the risks of MACCE and ST across all DES
types, with adjusted hazard ratios (HRs) for MACCE
ranging from 0.52 to 0.89 (50). The TAXUS Liberté
Post Approval Study was embedded in the DAPT
study as a surveillance of DES performance after
commercial release to fulﬁll an FDA requirement (57).
This exploratory analysis reported overall similar
results to the main ﬁndings of the DAPT trial, with
off-label use of prasugrel in patients who did not
all have ACS. It demonstrated that besides patient
characteristics and clinical setting (stable vs. un-
stable presentation), the type of stent also affected
clinical outcome. Consistent with meta-analyses
of ﬁrst-generation versus second-generation stents
(18,44,45), the safety of PES may be somewhat
improved by long-term use of prasugrel (58). Rather
than promoting VL-DAPT, this study supports no
longer using ﬁrst-generation DES, particularly pacli-
taxel stents.
A cohort of patients with BMS were included in
the DAPT trial. Among 10,026 propensity-matched
subjects, DES-treated subjects had a lower rate of
ST through 33 months compared with BMS-treated
subjects (1.70% vs. 2.61%; p ¼ 0.008) and a non-
inferior rate of MACCE (11.37% vs. 13.24%; non-
inferiority p < 0.001) (59). Results in BMS-treated
subjects randomized to VL-DAPT are consistent
with DES results in relation to ST and bleeding.
Interestingly, and in contrast to the DES-treated
patients, the BMS-treated cohort did not demon-
strate a difference in mortality between VL- and L-
DAPT. This information, in addition to the recently
published PEGASUS-TIMI 54 trial and Elmariah
meta-analysis, is reassuring (51,52).
TYPE OF P2Y12 ANTAGONIST. In the DAPT trial,
comparisons between speciﬁc thienopyridines may
be confounded, as the patients’ therapy was not
FIGURE 4 All-Cause Death in the 3 Studies Evaluating Very Long Duration of
DAPT ($24 Months)
DAPT
All
0.800
0.696
1.313
0.792
0.599
0.442
0.486
0.625
1.068
1.097
3.547
1.004
>12 months
worse
>12 months
better
p=0.054
DES-LATE
ARCTIC-interruption
Odds
ratio
DeathStudy name Odds ratio and 95% CI
Lower
limit
Upper
limit
0.1 1 10
Reproduced with permission from Montalescot G. Risk and beneﬁt of dual antiplatelet
therapy. Paper presented at: the American Heart Association, Late Breaking Clinical Trial
session; November 16, 2014. ARCTIC ¼ Assessment by a double Randomization of a
Conventional antiplatelet strategy versus a monitoring-guided strategy for drug-eluting
stent implantation and of Treatment Interruption versus Continuation 1 year after stenting;
DAPT ¼ dual antiplatelet therapy; DES-LATE ¼ Optimal Duration of Clopidogrel Therapy
With DES to Reduce Late Coronary Arterial Thrombotic Event.
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841randomly assigned. Although protection against
MACCE was signiﬁcant with clopidogrel (HR: 0.80), it
was more pronounced with prasugrel (HR: 0.52; p for
interaction ¼ 0.03). This data was conﬁrmed in the
TAXUS Liberte Post Approval Study, in which off-
label use of prasugrel was particularly effective
in reducing MI resulting from ST (0% vs. 2.6%;
p < 0.001) and from sites remote from the stent (1.9%
vs. 4.5%; p ¼ 0.007). Bleeding complications were
modestly and nonsigniﬁcantly increased with prasu-
grel, with no effect on mortality. The extended
follow-up 3 months after interruption of prasugrel
showed a particularly marked rebound of ischemic
events beyond 30 months, suggesting that prasugrel
was particularly effective in suppressing stent- and
nonstent-related thrombotic complications.
In the CHARISMA trial, among patients with prior
MI, ischemic stroke, or symptomatic peripheral arte-
rial disease (n ¼ 9,478), there was a signiﬁcant
reduction of the risk of MI, stroke, or death associated
with a combination of low-dose aspirin plus clopi-
dogrel compared with aspirin alone at 30 months
(60). The TRILOGY-ACS (The Targeted Platelet Inhi-
bition to Clarify the Optimal Strategy to Medically
Manage Acute Coronary Syndromes) study also
showed that, among the patients with angiographic
conﬁrmation of CAD after an ACS (n ¼ 3,085), treat-
ment with prasugrel and aspirin signiﬁcantly reduced
death, MI, or stroke compared with clopidogrel and
aspirin at 30 months (61). Similarly, in the TRA 2P-
TIMI 50 trial, vorapaxar, a protease-activated recep-
tor 1 inhibitor, reduced the composite risk of death,
MI, or stroke in patients with prior MI (n ¼ 17,779)
compared with the placebo group at 36 months (17).
The largest study examining the role of VL-DAPT in
secondary prevention is the PEGASUS-TIMI 54 trial
(51). This randomized, double-blind trial evaluated
the efﬁcacy and safety of ticagrelor in addition to
low-dose aspirin for long-term treatment of 21,162
patients in stable condition with a history of sponta-
neous MI 1 to 3 years before randomization. The
PEGASUS-TIMI 54 trial evaluated 2 intensities of an-
tiplatelet therapy using the 90-mg twice-daily dose of
ticagrelor studied in PLATO (The Study of Platelet
Inhibition and Patient Outcomes) as well as a lower
dose: 60 mg twice daily. Both doses of ticagrelor
reduced the risk of cardiovascular death, MI, or stroke
by 15% and doubled the risk of TIMI major bleeding.
The rates of fatal bleeding or nonfatal intracranial
hemorrhage did not differ signiﬁcantly between the
ticagrelor dose group and the placebo group. The
rates of bleeding and other side effects such as dys-
pnea were numerically lower with the 60-mg dose of
ticagrelor than with the 90-mg dose, resulting in alower rate of discontinuation of the study drug and a
better safety proﬁle with the 60-mg dose. There was a
trend with ticagrelor 60 mg twice daily toward a
reduction in the rate of cardiovascular death and
death from any cause, but this effect was not signif-
icant. For every 10,000 patients treated with tica-
grelor 60 mg twice daily, 42 ischemic events (death,
MI or stroke) per year would be prevented at the cost
of 31 TIMI major bleeding. All of these studies support
a role for extended and more potent antiplatelet
treatment for secondary prevention in patients with
proven CAD and, in particular, with a prior history of
MI. Interestingly, the subgroup of patients presenting
with acute MI in the DAPT trial had a reduction in
MACCE with continued thienopyridine that was
greater (HR: 0.56) than in patients without MI (HR:
0.83; interaction p ¼ 0.03). Bleeding, however, was
similarly increased in both subgroups (62). The
consistent excess of bleeding across studies with
prolonged DAPT suggests that patients should be
selected on the basis of the ischemic versus bleeding
risk.
ONGOING STUDIES. Alternative strategies with novel
therapies, as well as withdrawing some agents, repre-
sent an area of investigation that will add to our
understanding of optimal antiplatelet management
(63). A number of studies are examining the effec-
tiveness of shorter-duration DAPT in patients after
coronary stenting. The largest of these, GLOBAL
LEADERS (Comparative Effectiveness of 1 Month of Tica-
grelor Plus Aspirin Followed by Ticagrelor Monotherapy
Versus a Current-day Intensive Dual Antiplatelet Therapy
TABLE 5 Ongoing St
Study (Ref. #)
GLOBAL LEADERS
(NCT01813435)
REDUCE
(NCT02118870)
SMART-CHOICE
(NCT02079194)
SMART-DATE
(NCT01701453)
DAPT-STEMI
(NCT01459627)
TWILIGHT
(NCT02270242)
CVA ¼ cerebrovascular acc
Myocardial Infarction; GLO
All-comers Patients Underg
in Patients With Acute Coro
UndergOing Implantation
Intervention in Patients Wi
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842in All-comers Patients Undergoing Percutaneous Coro-
nary Intervention With Bivalirudin and BioMatrix
Family Drug-eluting Stent Use; NCT01813435) will
randomize 16,000 patients receiving the Biomatrix
DES (Biosensors Interventional Technologies, Singa-
pore) to either 1 month of DAPT with aspirin and tica-
grelor followed by 23 months of ticagrelor alone, or 12
months of standard DAPT followed by aspirin mono-
therapy. Other randomized studies are also exploring
the safety of shorter durations of DAPT with novel
stent platforms, and some will focus on the ACS pop-
ulation receiving newer-generation DES. The TWI-
LIGHT (Ticagrelor With Aspirin or Alone in High-Risk
Patients After Coronary Intervention) study [NCT0227
0242] takes a new approach to SAPT. The active arm
will have interruption of aspirin at 3 months post-PCI
continuing on ticagrelor alone. The comparator arm
will have DAPT with aspirin and ticagrelor for 1 year
(Table 5). Other smaller studies evaluating long-term
DAPT in stented populations (NCT02079194) are still
ongoing.
THE CLINICIAN’S CHOICE
Medicine is both art and science. The science relies on
data provided by randomized clinical trials and
observational studies elucidating incidence, risk fac-
tors, effect on outcomes, and optimal treatment for a
medical condition. The art relies on the ability of the
physician to synthesize medical knowledge and
translate it into the optimal patient-speciﬁc manage-
ment strategy. The decision to either continue or stop
DAPT after a mandatory period after the implantationudies Examining Abbreviated Duration of DAPT
Design Size
Active
(Months)
Control
(Months) Population
RCT
(Biomatrix stent)
16,000 1 12 DES
RCT
(COMBO dual
therapy stent)
1,500 3 12 ACS
RCT 5,100 3 12 DES
RCT 3,000 6 12 ACS
RCT 1,100 6 12 STEMI
RCT 8,000 3 12 complex PCI
with DES
ident; DAPT-STEMI ¼ Prospective, Randomized, Open Label Trial of 6 Months vs. 12 Mon
BAL LEADERS ¼ Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed b
oing Percutaneous Coronary InterventionWith Bivalirudin and BioMatrix Family Drug-eluting
nary Syndrome Treated With the COMBO Dual-therapy stEnt; SMART-CHOICE ¼ Compariso
of Coronary Drug-Eluting Stents; SMART-DATE ¼ Smart Angioplasty Research Team: Safe
th Acute Coronary Syndromes; TWILIGHT ¼ Ticagrelor With Aspirin or Alone in High-Risk Patof a DES perfectly reﬂects this concept (64). An initial
mandatory period of DAPT after DES implantation
is needed to prevent stent- and nonstent-related
thrombotic complications. During this period, cessa-
tion of DAPT is associated with an unacceptably high
rate of thrombotic events (65–67). The duration of
mandatory DAPT,which can range from 3 to 12months,
depends on the patient’s clinical presentation, overall
risk proﬁle, lesion complexity, and the type of stent
implanted. Beyond the mandatory period, DAPT pro-
longation has to be carefully considered (68). Exten-
sion of DAPT confers protection against stent- and
nonstent-related atherothrombotic events (50). How-
ever, the antithrombotic beneﬁt may be counter-
balanced by an increased bleeding risk, which affects
morbidity and mortality and cannot be disregarded.
Therefore, a realistic estimation of the long-term
ischemic and bleeding risk in every patient undergo-
ing PCI is of paramount importance to tailor the
optimal DAPT duration.
ISCHEMIC RISK EVALUATION. Coronary thrombotic
events after PCI can be classiﬁed as stent- and
nonstent-related (69). DAPT confers protection on
both types of thrombotic events through suppression
of platelet reactivity and aggregability (70).
The pathophysiology of ST includes patient-, stent-,
and procedure-related factors (71). Patient-related
factors include presentation with ACS (in which
STEMI carries the highest thrombotic risk), diabetes
mellitus, chronic kidney disease, and clinical surro-
gates such as multivessel CAD, previous MI, left ven-
tricular dysfunction, and high on-treatment platelet
reactivity (65–67,72,73). Procedural factors includePrimary EP
Expected
Completion Date
Composite of all-cause mortality or nonfatal new
Q-wave MI up to 2 yrs post-randomization
June 2016
Composite of all-cause mortality, MI, ST, stroke,
or bleeding at 12 months
March 2017
Composite of death, MI, cerebrovascular events,
or bleeding over 3–12 months after the
index procedure
February 2020
Composite of death, MI, CVA, ST, or major bleeding
over 6–18 months post-hospitalization
August 2016
Composite of death, MI, revascularization, CVA,
or bleeding at 18 months post-randomization
December 2017
Major bleeding at 15 months post-PCI March 2017
ths Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation
y Ticagrelor Monotherapy Versus a Current-day Intensive Dual Antiplatelet Therapy in
Stent Use; REDUCE¼ Randomized Evaluation of Short-termDUal Anti Platelet Therapy
n Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients
ty of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary
ients After Coronary Intervention; other abbreviations as in Tables 1 to 3.
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843stent underexpansion or undersizing, incomplete
stent apposition, residual edge dissection, number of
stents implanted, ﬁnal stent length, and lesion
complexity. Finally, stent-related factors include
polymer hypersensitivity with incomplete endotheli-
alization, stent design, and strut thrombogenicity.
A substantial improvement in stent endothelialization
and strut thrombogenicity has been achieved with
second-generation DES, as compared with their
predecessors (18). Moreover, bioresorbable polymer
DES have the potential advantage of eliminating
polymer-related triggers for late and very late ST after
the elution of the antirestenotic drugs (44).
The PROSPECT (Providing Regional Observations
to Study Predictors of Events in the Coronary Tree)
study demonstrated that adverse ischemic events
occurring at follow-up after PCI for ACS are almost
equally distributed between thrombosis in culprit and
nonculprit lesions (69). Neoatherosclerosis can occur
either inside or outside of the stented vascular
segment (74). Evidence from intravascular imaging
and histologic studies in DES demonstrate the
occurrence of continuous neointimal growth (75). In-
stent neoatherosclerosis may be an important mech-
anism of stent failure, accounting for both ST and
restenosis after either BMS or DES implantation (74).
Having considered these factors, the prolongation
of DAPT after the mandatory period to prevent the
occurrence of future thrombotic events, both within
and beyond the target coronary lesion, may be an
attractive and “desirable” strategy after meticulous
individualized evaluation of the hemorrhagic risk.
BLEEDING RISK EVALUATION. As opposed to ST
or recurrent MI, bleeding severity ranges from
events that are clinically insigniﬁcant to those that
are life-threatening or fatal (76). Among existing,
commonly-used deﬁnitions, Bleeding Academic
Research Consortium type 3 or 5, TIMI major or
minor, and GUSTO moderate or severe bleeding may
seriously affect morbidity and mortality and, there-
fore, should be considered clinically relevant (77,78).
Several risk scores have been developed to predict
late and very late bleeding, most of which do not
apply speciﬁcally to a PCI population (79). For
example, the HAS-BLED (hypertension, abnormal
renal/liver function, stroke, bleeding history or pre-
disposition, labile international normalized ratio,
elderly, drugs/alcohol concomitantly) risk score was
developed to predict bleeding in patients on chronic
anticoagulation for atrial ﬁbrillation and is not rele-
vant to PCI patients (79). Other risk factors, such as
malignancy, thrombocytopenia, anemia, white blood
cell count, low platelet reactivity, excessive fall risk,and genetic factors have been described (80–83).
Considering the heterogeneity of risk factors and
potential sites for bleeding, the individual bleeding
risk should be carefully evaluated.
IMPORTANCE OF THE CLINICAL CHOICE. Clinically
signiﬁcant bleeding events are numerically more
frequent than ST or MI, and their effect on late mor-
tality has been extensively described (50,82). In
addition, for some patients or clinicians, a moderate
bleed may not carry the same weight as an ST or
spontaneous MI. On the basis of data derived from
early events after PCI, ST is associated with a higher
fatality rate than major bleeding (84,85).
Pooling the available evidence, prolonging DAPT
after the mandatory period seems to be more appro-
priate in patients at high risk for ischemic events and
relatively low bleeding risk. Conversely, considering
the greater safety of newer-generation DES, the rela-
tively high incidence of late bleeding events on DAPT,
and their deleterious effect on survival, limiting
DAPT to the 3- to 6-month mandatory period may be
the optimal strategy in patients at moderate or high
risk for bleeding. Similarly, the strategy of S-DAPT
would apply to patients who would require oral
anticoagulation (e.g., for atrial ﬁbrillation) or semi-
urgent noncardiac surgery (e.g., for cancer) or inves-
tigation (e.g., gastrointestinal endoscopy). Ideally,
prescription of DAPT after PCI with DES has to be a
dynamic (i.e., potentially modiﬁable over time) re-
commendation. After the procedure, patients should
be prescribed DAPT for the initial mandatory period
of 3 to 6 or 12 months according to clinical presenta-
tion, ischemic risk, bleeding risk, and the type of
stent implanted. After this initial mandatory period,
the physician may face 3 main scenarios regarding the
risk/beneﬁt ratio of a potentially “desirable” longer
DAPT recommendation:
1. Patient had a recurrent ischemic event on DAPT;
these patients will probably beneﬁt from prolong-
ing DAPT.
2. Patient had clinically signiﬁcant bleeding; these
patients should stop DAPT or at least complete the
minimal mandatory period.
3. Patient is event-free; patients at low risk for
bleeding and at high risk for ischemia may beneﬁt
from DAPT prolongation, considering the beneﬁ-
cial effect of DAPT in preventing stent- and
nonstent-related thrombotic events. Conversely,
patients at moderate or high risk for bleeding may
beneﬁt from DAPT cessation. Finally, patients may
present with both high bleeding risk and high
ischemic risk, and this is when the science of
medicine becomes art (64).
CENTRAL ILLUSTRATION Decision-Making After the Mandatory DAPT Period
Drug-eluting coronary stent implantation
Mandatory period of DAPT
STOP DAPT AFTER MANDATORY PERIOD CONTINUE WITH DAPT
Comprehensive clinical evaluation
ISCHEMIC RISK OUTWEIGHS BLEEDING RISK
Patient presentation:
• Recurrent ischemic
event on DAPT
• Stent-related complications
• Acute coronary syndrome
• Male
• Diabetes mellitus
• Left ventricular
dysfunction
• Chronic kidney disease
• Peripheral vascular disease
• Prior ischemic stroke
BLEEDING RISK OUTWEIGHS ISCHEMIC RISK
Patient presentation:
• Clinically significant 
bleeding on DAPT 
• Advanced age 
• Female
• Liver disease
• Peptic ulcer disease
• Chronic oral nonsteroidal 
anti-inflammatory drug 
(NSAID) therapy
• Anemia and/or 
thrombocytopenia
• Uncontrolled hypertension
• Bleeding diathesis
• Prior major bleeding/
prior hemorrhagic stroke
• Atrial fibrillation/chronic 
anticoagulation therapy
• High bleeding risk score
UNFAVORABLE PROFILE
Clinical considerations:
• Short life
expectancy
• Poor socio-
economic status
• Poor expected
DAPT adherence
• Poor mental status
• Malignancy
• End stage
renal failure
• Smoker
• Clopidogrel 
nonresponsiveness
• Prior myocardial infarction
• Lesion complexity
• Incomplete stent apposition
• Stent undersizing/
underexpansion
• Residual edge dissection
• Stent deployment in
necrotic core
• Stent overlap
Montalescot, G. et al. J Am Coll Cardiol. 2015; 66(7):832–47.
When a mandatory period of DAPT is completed, a careful evaluation of the patient’s ischemic risk and bleeding risk, and of the overall clinical proﬁle should be
undertaken. DAPT ¼ dual antiplatelet therapy; NSAID ¼ nonsteroidal anti-inﬂammatory drug.
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may inﬂuence the beneﬁt/risk ratio or tolerance of or
compliance with DAPT should be evaluated before
deciding whether to prolong DAPT or not. A summary
of the factors to consider in deciding whether to
continue or discontinue DAPT after a mandatory
period is depicted in the Central Illustration.
Finally, a very important and often underestimated
aspect of post-procedural PCI management is optimal
medical therapy (OMT). The control of multiple car-
diovascular risk factors reduces the incidence of car-
diovascular events (86). OMT is a broad term that
incorporates the control of lifestyle risk factors
(weight loss, smoking cessation, dietary regimen,
exercise, and life rhythms) and speciﬁc pharmaco-
therapy to control arterial hypertension, hyperlipid-
emia, and chronic hyperglycemia. As stated by the
European Society of Cardiology guidelines “OMT
should not be considered an alternative but a syner-
gistic approach to revascularization” (26).CONCLUSIONS
Considering the consistent results from the reported
studies, safe interruption of DAPT 6 months after DES
implantation may be possible in selected patients.
Two randomized studies and a few registries have
suggested that 3 months of DAPT was possible with
the latest DES generation.
Prolongation of DAPT beyond 1 year after DES
implantation is possible. This has been tested now in
patients selected after a year of follow-up. The
strategy of using DAPT to reinforce secondary pre-
vention is more sensible in patients at high ischemic
risk, although the beneﬁt was observed across
almost all subgroups. Long-term DAPT reduces
stent- and nonstent-related thrombotic events at the
cost of more bleeding complications, translating into
no survival advantage. Long-term DAPT may use
clopidogrel or a new oral P2Y12 antagonist. In either
case, removing the P2Y12 antagonist exposes patients
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845to a reactivation of the ischemic disease, even 2
years after stenting. Removing the last antiplatelet
agent is not recommended in any coronary patient.
Finally, after a short mandatory period of 3 to
6 months, DAPT should be tailored over time on the
basis of the clinical proﬁle, the type of stent, and the
patient’s tolerance, comorbidities, and preference.
At this stage, clinicians are advised to individualizedecisions regarding the type and duration of DAPT in
stented patients.
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